Biography - Dr Paul Jenkins MA BChir MD FRCP

Name: Dr Paul Jenkins MA BChir MD FRCP
...
Position: Consultant Physician and Endocrinologist
The London Endocrine Centre
68 Harley Street
London W1G 7HE
Clinical interests: Thyroid disorders
Primary Hyperparathyroidism  
Adrenal and Pituitary disease
Male ‘menopause’
Diabetes Mellitus
Hormone deficiencies
Chronic fatigue
Professional Profile

After qualifying with a degree in Medical Sciences at Cambridge University, Dr Jenkins undertook his clinical training at The Royal London Hospital. Shortly afterwards he joined the internationally renowned Department of Endocrinology at St Bartholomew’s Hospital, where he gained unrivalled experience in clinical endocrinology. After completing his MD research degree he was appointed as Senior Lecturer and then Reader in Endocrinology and Honorary Consultant Endocrinologist. For over 10 years he also led the Endocrine service at Homerton University Hospital. Within the Medical School, he was Dean for Pre-Registration Doctors and an enthusiastic teacher of undergraduate students across all years. He led an active research group into the interactions between hormones and cancer and has published more than 80 peer-reviewed scientific papers in this field as well as writing several books and text-book chapters. He was awarded numerous academic grants for his research and was invited to lecture extensively in the UK and abroad on his findings.

Several years ago, he decided to devote more time to clinical work and after 20 years in practice established The London Endocrine Centre where he is the senior consultant. Dr Jenkins has a particular interest in disorders of the thyroid, adrenal and pituitary glands, as well as diabetes. He has also developed considerable expertise in the diagnosis and management of chronic fatigue with patients travelling from across the UK to consult with him for this. He firmly believes in a holistic approach to his patients with his consultations allowing plenty of time to discuss all their concerns and wishes before fully involving them in a shared approach to their optimum management. He believes that rather than be rigidly beholden to laboratory ‘normal ranges’, the optimum care of a patient’s condition frequently requires an understanding of their symptoms in conjunction with appropriate interpretation of laboratory results and diagnostic imaging.  His patient feedback is excellent and patients particularly appreciate the time he takes to listen to them, impart clinical information in a readily understandable manner and involve them in a structured and carefully thought out management plan to help them get better. 

Appointments: T: 020 7323 2755
F: 0207 436 5756
E: info@londonendocrinecentre.co.uk
Consultations/Practice: The London Endocrine Centre
68 Harley Street
London W1G 7HE

The London Independent hospital
1 Beaumont Square
London E1                                                

Professional Bodies General Medical Council - Specialist Register
And Societies Society for Endocrinology
The Endocrine Society
Royal College of Physicians
Royal Society of Medicine
Care Quality Commission: Dr Jenkins is fully registered with the Care Quality Commission and a copy of his recent evaluation is available to view.
Patient Feedback: Dr Jenkins performs regular audit of patient satisfaction. The most recent results are available here

Publications in Peer-Reviewed Journals:

1. IGFBP-1: A Metabolic Signal Associated With Exercise - Induced Amenorrhoea.
PJ Jenkins, X Ibanez-Santos, J Holly, A Cotterill, L Perry, R Wolman, M Harries, A Grossman
Neuroendocrinology 1993; 57: 600-603
2. The Control of the GnRH Pulse Generator With Respect to Opioid and Nutritional Cues.
PJ Jenkins and A Grossman
Human Reproduction 1993; 8:154-161
3. Adrenocorticotrophin - independent Unilateral Macronodular Adrenal Hyperplasia and Coexistant Myelolipoma: An Unusual Cause of Cushing's Syndrome.
PJ Jenkins, SL Chew, DG Lowe, RH Reznek, JAH Wass
Clinical Endocrinology 1994 41: 827-830
4. Gender Differences in Incidence of Idiopathic Fistula-in-ano Are Not Explained by Circulating Sex Hormones.
PJ Lunniss, PJ Jenkins , GM Besser, LA Perry, Phillips RKS
International Journal of Colorectal Disease 1995 10 25-28
5. The Long-term Outcome After Adrenalectomy and Prophylactic Pituitary Radiotherapy for Cushing's Disease
PJ Jenkins , PJ Trainer, PN Plowman, WS Shand, JAH Wass, AB Grossman, GM Besser
Journal of Clinical Endocrinology and Metabolism 1995 80 165-171
6. Lymphocytic Hypophysitis: Unusual Features of a Rare Disorder
PJ Jenkins , SL Chew, DG Lowe, M Charlesworth, GM Besser, JAH Wass
Clinical Endocrinology 1995 42 529-534
7. Are Activating Mutations of the Adrenocorticotropin Receptor Involved in Adrenal Cortical Neoplasia?
K Light, PJ Jenkins , A Weber, C Perrett, A Grossman, M Pistotrello, SL Asa, RN Clayton, AJL Clark
Life Sciences 1995 56 1523-1527
8. The Roles of Gallbladder Emptying and Intestinal Transit in the Pathogenesis of Octreotide-Induced Gallbladder Stones.
SH Hussaini, SP Pereira, C Kennedy, PJ Jenkins , GM Murphy, JAH Wass, RH Dowling
Gut 1996 38 775-783
9. Oral Prednisolone Supplementation Abolishes the Acute Adverse Effects Following Initiation of Depot Bromocriptine Therapy
PJ Jenkins , A Jain, SL Jones, GM Besser, AB Grossman
Clinical Endocrinology 1996 45 447-452**
** Selected for the 1998 Year Book of Endocrinology (Ed: Dr M Molitch; publishers Mosby-Year Book Inc)
10. Outcome of Transsphenoidal Surgery for Acromegaly Using Strict Criteria for Surgical Cure
R Sheaves, PJ Jenkins , P Blackburn , AH Huneidi, F Afshar , AB Grossman, GM Besser, JAH Wass
Clinical Endocrinology 1996 45 407-413
11. Intracardiac Metastases from Neuroendocrine Tumours
W Drake, PJ Jenkins , RR Phillips, DG Lowe, AB Grossman, GM Besser, JAH Wass
Clinical Endocrinology 1997 46 517-522
12. Acromegaly, Colonic Polyps and Carcinoma
PJ Jenkins , PD Fairclough, T Richards, DG Lowe, J Monson , AB Grossman, JAH Wass, GM Besser
Clinical Endocrinology 1997 47 17-22
13. Metastatic Parathyroid Carcinoma in the MEN 2A Syndrome
PJ Jenkins , M Satta, M Simmgen, WM Drake, C Williamson, DG Lowe, K Britton, SL Chew, RV Thakker, GM Besser
Clinical Endocrinology 1997 47 747-751  
14. Cancer in Acromegaly
PJ Jenkins
Trends in Endocrinology and Metabolism 1998 9 :360-366
15. Prolonged Large Bowel Transit Increases Serum Deoxycholic Acid - a Risk Factor for Octreotide-Induced Gallbladder Stones
MJ Veysey, LA Thomas, AI Mallet, PJ Jenkins , GM Besser, JAH Wass, GM Murphy, RH Dowling
Gut 1999 44 675-681  
16. The Influence of Plasma on Basal and ACTH-stimulated in vitro Adrenocortical Steroidogenesis
PJ Jenkins , TA Cross, LA Perry, S Medbak , AJL Clark, GM Besser
Journal of Endocrinology 1999 162 155-161
17. Growth Hormone and Exercise
PJ Jenkins
Clinical Endocrinology 1999 50 683-689
18. Colorectal Neoplasia in Acromegaly
PJ Jenkins , GM Besser, PD Fairclough
Gut 1999 44 585-587
19. Adrenal Enlargement and Failure of Suppression of Circulating Cortisol by Dexamthasone in Patients with Malignancy
PJ Jenkins , SA Sohaib, PJ Trainer, TA Lister, AJ Clark, GM Besser, RH Reznek
British Journal of Cancer 1999 80 1815-1819
20. Detection of GH Doping
P.J. Jenkins
The Lancet 1999 353 1532
21. Respiratory Muscle Strength in Cushing's Syndrome
GH Mills, D Kyroussis, P Jenkins , C Hamnegard , MI Polkey, JAH Wass, GM Besser, J Moxham, M Green
American Journal of Respiratory and Critical Care Medicine 1999 160 1762-1765
22. Colorectal Neoplasia in Acromegaly
PJ Jenkins , PD Fairclough, GM Besser
Gut 1999
23. Menstrual Irregularity in Women with Acromegaly
GA Kaltsas, JJ Mukherjee, PJ Jenkins , MA Satta, N Islam, JP Monson, GM Besser, AB Grossman
Journal of Clinical Endocrinology and Metabolism 1999 84 2731-2735
24. Hypothalamo-Pituitary Abnormalities in Adult Patients with Langerhan's Cell Histiocytosis: Clinical, Endocrinological and Radiological Features and Response to Treatment
GA Kaltsas, TB Powles, J Evanson, PN Plowman, JE Drinkwater, PJ Jenkins , JP Monson, GM Besser, AB Grossman
Journal of Clinical Endocrinology and Metabolism 2000 85 1370-1376
25. Low Expression of the Cell Cycle Inhibitor p27 in Normal Corticotroph Cells, Corticotroph Tumours and Malignant Pituitary Tumours
K. Lidhar, M. Korbonits, S. Jordan, Z. Khalimova, G. Kaltsas, X. Lu, R.N. Clayton, P.J. Jenkins , J.P. Monson, G.M Besser, D.G. Lowe, A.B. Grossman
Journal of Clinical Endocrinology and Metabolism 1999 84 3823-3830
26. Alterations in Serum Protein Levels in Patients with Cushing's Syndrome Before and After Successful Treatment
P. Putignano, G.A. Kaltsas, M. Korbonits, P.J. Jenkins , J.P. Monson, G.M. Besser, A.B. Grossman
Journal of Clinical Endocrinology and Metabolism 2000 85 3309-3312
27. IGF-I and the Development of Colorectal Neoplasia in Acromegaly
P.J. Jenkins , V. Frajese, A-M. Jones, C. Camacho-Hubner, D.G. Lowe, P.D. Fairclough, S.L. Chew, A.B. Grossman, J.P. Monson, G.M. Besser
Journal of Clinical Endocrinology and Metabolism 2000 85 3218-3221
28. The Pathobiology of Median Neuropathy in Acromegaly
PJ Jenkins , S.A. Sohaib, S Akker, R.R. Phillips, K. Spillane, J.A.H. Wass, J.P. Momson, A.B. Grossman, G.M. Besser, R.H. Reznek
Annals of Internal Medicine 2000 133 197-201
29. Uterine Leiomyomata in Women with Acromegaly
G Kaltsas, PJ Jenkins, J. Webb, JP Monson, GM Besser, A Grossman
Journal of Clinical Endocrinology and Metabolism 85 2000 1347
30. The Use of Long-acting Somatostatin Analogues in Acromegaly
P.J. Jenkins
Growth Hormone and IGF Research 2000 10 Suppl B: S111-114
31. Acromegaly and Colon Cancer
P.J. Jenkins
Growth Hormone and IGF Research 2000 10 Suppl A:S35-S36
32. Optimal Dosage Interval for Depot Somatostatin Analogue Therapy in Acromegaly Requires Individual Titration
P.J.Jenkins, S. Akker, S.L. Chew, G.M. Besser, J.P. Monson, A.B. Grossman
Clinical Endocrinology 2000 53 719-724
33. Sustained Reduction in Circulating Cholesterol in Adult Hypopituitary Patients Given Low Dose Titrated Growth Hormone Replacement Therapy: a Two Year Study
D. Florakis, V. Hung, G. Kaltsas, D. Coyte, P.J. Jenkins, S.L. Chew, A.B. Grossman, G.M. Besser, J.P. Monson
Clinical Endocrinology 2000 53 453-462
34. Comparison of Somatostatin Analog and Metaiodobenzylguanidine (MIBG) Radionuclides In The Diagnosis and Localisation of Advanced Neuroendocrine Tumors
G. Kaltsas, M. Korbonits, E. Heintz, J.J. Mukherjee, P.J. Jenkins, S.L. Chew, J.P. Monson, G.M. Besser, K.E. Britton, A.B. Grossman
Journal of Clinical Endocrinology and Metabolism 2001 86 895-902
35. Predictors of the Outcome of Surgical Treatment in Acromegaly and the Value of the Mean Growth Hormone Day Curve in Assessing Postoperative Disease Activity
GA Kaltsas, AM Isidori, D Florakis, PJ Trainer, C Camacho-Hubner, F Afshar, I Sabin, PJ Jenkins, SL Chew, JP Monson, GM Besser, AB Grossman
Journal of Clinical Endocrinology and Metabolism 2001 86 1656-1652
36. Increased Levels of Insulin-like Growth Factor Binding Protein-2 in Serum and Tumours and Sera From Patients with Colonic neoplasia with and without Acromegaly
F Miraki-Moud, PJ Jenkins, PD Fairclough, S Jordan, AM Jones, DG Lowe, JP Monson, AB Grossman, GM Besser, C Camacho-Hubner
Clinical Endocrinology 2001 54 499-508
37. Acromegaly and Cancer: A Problem
PJ Jenkins and GM Besser
Journal of Clinical Endocrinology and Metabolism 2001 86 2935-2941
38. The Growth Hormone/ Insulin-like Growth Factor-I Axis and Colorectal Cancer
SA Bustin and PJ Jenkins
Trends in Molecular Medicine 2001 7 447-454
39. Colorectal neoplasia in acromegaly
PJ Jenkins and PD Fairclough
Clinical Endocrinology 2001 55 727-730
40. Colonic Transit Influences Deoxycholic Acid Kinetics
M.J Veysey, L.A. Thomas, A.I. Mallet, PJ Jenkins, GM Besser, GM Murphy, RH Dowling
Gastroenterology 2001 121 812-822
41. Effects of cisapride on gall bladder emptying, intestinal transit, and serum deoxycholate: a prospective, randomised, double blind, placebo controlled trial
MJ Veysey, P Malcolm, AI Mallet, PJ Jenkins, GM Besser, GM Murphy, RH Dowling
Gut 2001 49 828-834
42. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta- iodobenzylguanidine [(131)I-mIBG]
Mukherjee,J.J.; Kaltsas,G.A.; Islam,N.; Plowman,P.N.; Foley,R.; Hikmat,J.;
Britton,K.E.;PJ Jenkins; Chew,S.L.;Monson,J.P.;Besser,G.M.;Grossman,A.B.
Clinical Endocrinology 2001 55 47-60
43. Growth hormone and exercise: physiology, use and abuse
PJ Jenkins
Growth Hormone and IGF-I Research 2001 11 (suppl A) S71-77  
44. Down-regulation of 25-hydroxyvitamin D-1-a-hydroxylase mRNA in the normal colon of patients with colorectal cancer.
Ogunkolade,BW, Boucher, BJ, Fairclough,PD, Hitman, GA, Dorudi S, Jenkins PJ, Bustin SA.
The Lancet 2002 359 1831-1832
45. Growth hormone replacement does not increase serum prostate-specific antigen in hypopituitary men over 50 years
CW le Roux, PJ Jenkins, SL Chew, C Camacho-Hubner, AB Grossman, GM Besser, JP Monson
European Journal of Endocrinology 2002 147 1-5
46. Expression of the growth hormone/ IGF-I axis influences angiogenesis in colorectal cancer
SA Bustin, W Ogunkolade, S Patel, S Khalaf, R Feakins S Dorudi, PJ Jenkins
Tumour Biology 2002 23 130-138
47. Doping in Sport
PJ Jenkins
The Lancet 2002 360 No 9327 99-100
48. The mRNA expression of cyclo-oxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in human breast cancer
K Kirkpatrick, W Ogunkolade, A Elkak, S Bustin, P Jenkins, M Ghilchik, K Mokbel.
Curr.Med.Res.Opin.2002 18 237-241
49. Neurosurgical treatment of Nelson’s syndrome
PA Kelly, G Samandouras, AB Grossman, F Afshar, GM Besser and PJ Jenkins
Journal of Clinical Endocrinology and Metabolism 2002 87 5465-5469
50. Screening guidelines for colorectal cancer and polyps in patients with acromegaly
PJ Jenkins and PD Fairclough
Gut 2002 51 (suppl 5) V13-14
51. The GH/IGF-I axis and breast cancer.
C Laban, SA Bustin and PJ Jenkins
Trends in Endocrine and Metabolism 2003 14 28-34
52. hTERT expression in human breast cancer and non-cancerous breast tissue: correlation with tumour stage and c-Myc expression
Kirkpatrick KL, Ogunkolade W, Elkak AE, Bustin S, Jenkins P, Ghilchick M, Newbold RF, Mokbel K
Breast Cancer Research And Treatment 2003 77 (3): 277-284
53. The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women.
Kaltsas,G.A.; Isidori,A.M.; Kola,B.P.; Skelly,R.H.; Chew,S.L.; Jenkins,P.J.; Monson,J.P.; Grossman,A.B.; Besser,G.M.
J.Clin.Endocrinol.Metab 2003 88 2634-26
54. IGF-1 levels, leg extensor power and physical performance after proximal femoral fracture.
Barber M, Braid V, Gilmore D, Grant SJ, Camacho-Hubner C, Jenkins PJ et al. Age Ageing 2003; 32(6):678-680.
55. Modulation of Cortisol Metabolism during Treatment of Acromegaly Is Independent of Body Composition and Insulin Sensitivity.
Frajese,G.V.; Taylor,N.F.; Jenkins,P.J.; Besser,G.M.; Monson,J.P.
Hormone Research 2004 61 246-251
56. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
P.J. Jenkins, M. Emery, S.J. Howling, J. Evanson, G.M. Besser, J.P. Monson
Hormone Research 2004 62 227-232
57. Evidence for a link between IGF-I and cancer
P.J.Jenkins and S.A.Bustin
European Journal of Endocrinology 2004 151 S17-22
58. Acromegaly and Cancer
P.J.Jenkins
Hormone Research 2004 62 (suppl 1) 108-115
59. Differential Expression of IGFBP-3 in Normal and Malignant Colon and its Influence on Apoptosis
P.J. Jenkins, S. Khalaf, W. Ogunkolade, K. McCarthy, T. David, R.E. Hands, D. Davies, and S.A. Bustin
Endocrine Related Cancer 2005 12 891-901
60. Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas. Woo YS, Isidori AM, Wat WZ, Kaltsas GA, Afshar F, Sabin I, Jenkins PJ, Monson JP, Besser GM, Grossman AB. J Clin Endocrinol Metab. 2005 Aug;90(8):4963-9.
61. The Ectopic Acth Syndrome: Clinical Features, Diagnosis, Management And Long- Term Follow-Up.
Isidori,A.M.; Kaltsas,G.A.; Pozza,C.; Frajese,V.; Newell-Price,J.; Reznek,R.H.; Jenkins,P.J.; Monson,J.P.; Grossman,A.B.; Besser,G.M.
J.Clin.Endocrinol.Metab 2005
62. Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas
Woo,Y.S.; Isidori,A.M.; Wat,W.Z.; Kaltsas,G.A.; Afshar,F.; Sabin,I.; Jenkins,P.J.; Monson,J.P.; Besser,G.M.; Grossman,A.B.
J.Clin.Endocrinol.Metab 2005 90 4963-4969
63. Does Growth Hormone Cause Cancer?
PJ Jenkins, A Mukherjee and SM Shalet
Clinical Endocrinology 2006 64 115-121
64. Conventional Pituitary Irradiation is Effective in Lowering Serum Growth Hormone and Insulin-Like Growth Factor-I in Patients with Acromegaly
P.J. Jenkins, P. Bates, M.N. Carson, P.M. Stewart, J.A.H. Wass on behalf of the UK National Acromegaly Register Study Group
J.Clin.Endocrinol.Metab 2006 91 1239-1245
65. Cyclo-oxygenase-2 (COX-2) mRNA expression and hormone receptor status in breast cancer.
K. McCarthy, S. Bustin, C. Laban, W. Ogunkolade, S Khalaf, R. Carpenter and
P.J. Jenkins.
European Journal of Surgical Oncology 2006 Sep;32(7):707-9.
66. Screening Guidelines for Colorectal Cancer and Polyps in Patients with Acromegaly
PJ Jenkins and PD Fairclough. Gut 2002; 51:v13-v14
67. Extended silencing of the IGF-I receptor gene signalling in MCF-7 cells by serialtransfection with siRNA. C. McVittie, S.Khalaf, W. Ogunkolade, V.M. Macaulay, R. Carpenter, S.A. Bustin, P.J.Jenkins. Analytical Biochemistry 2004
68. The management of differentiated thyroid cancer using 123I for imaging to assess the need for 131I therapy. Ali N, Sebastian C, Foley RR, Murray I, Canizales AL, Jenkins PJ, Drake WM, Plowman PN, Besser GM, Chew SL, Grossman AB, Monson JP, Britton KE.
Nucl Med Commun. 2006 Feb;27(2):165-9.
69. Growth hormone deficiency and replacement in patients with treated Cushing's Disease, prolactinomas and non-functioning pituitary adenomas: effects on body composition, glucose metabolism, lipid status and bone mineral density. Colson A, Brooke AM, Walker D, Besser GM, Chew SL, Grossman AB, Jenkins PJ, Drake WM, Monson JP. Horm Res. 2006;66(6):257-67.
70. Cancers associated with acromegaly. Jenkins PJ. Neuroendocrinology. 2006;83(3-4):218-23.
71. The role of hormone replacement therapy in healthy elderly men.
Jenkins PJ. Nat Clin Pract Urol. 2006 Sep;3(9):470-1.
72. Selective parathyroid venous sampling in patients with complicated hyperparathyroidism. Ogilvie CM, Brown PL, Matson M, Dacie J, Reznek RH, Britton K, Carpenter R, Berney D, Drake WM, Jenkins PJ, Chew SL, Monson JP. Eur J Endocrinol. 2006 Dec;155(6):813-21.
73. Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients. Agha A, Walker D, Perry L, Drake WM, Chew SL, Jenkins PJ, Grossman AB, Monson JP. Clin Endocrinol (Oxf). 2007 Jan;66(1):72-7.
74. Role of fasting plasma glucose, glycated haemoglobin and homeostatic model assessment in the detection of glucose intolerance in adult hypopituitary patients during growth hormone replacement therapy. Colson A, Walker D, Besser GM, Grossman AB, Chew SL, Jenkins PJ, Drake WM, Monson JP. Hormone Research. 2008;69(2):83-8.
75. The expression and function of IGFBP-3 in normal and malignant breast tissue.
McCarthy K, Laban C, McVittie CJ, Ogunkolade W, Khalaf S, Bustin S, Carpenter R, Jenkins PJ. Anticancer Research 2009 Oct;29(10):3785-90.
76. Expression of 25-hydroxyvitamin D-1-alpha-hydroxylase, and vitamin D receptor mRNA in normal and malignant breast tissue. McCarthy K, Laban C, Bustin SA, Ogunkolade W, Khalaf S, Carpenter R, Jenkins PJ. Anticancer Research. 2009 Jan;29(1):155-7.
77. A single-center open-label study to investigate the efficacy and safety of repeated subcutaneous injections of lanreotide Autogel in patients with acromegaly previously treated with octreotide. Kelly P, Maher KT, Chew SL, Monson JP, Grossman AB, Jenkins PJ. Endocrine Practice 2010 Mar-Apr;16(2):191-7.
78. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD, Eaden JA, Rutter MD, Atkin WP, Saunders BP, Lucassen A, Jenkins P, Fairclough PD, Woodhouse CR; British Society of Gastroenterology; Association of Coloproctology for Great Britain and Ireland. Gut. 2010 May;59(5):666-89.
79. Repeated colonoscopic screening of patients with acromegaly: 15 year experience identifies those at risk of new colonic neoplasia and allows for effective screening guidelines. Dworakowska D, Gueorguiev M, Kelly P, Monson J, Besser GM, Chew S, Akker S, Drake W, Fairclough P, Grossman A, Jenkins P. European Journal of Endocrinology. 2010 Apr 30.
80.

Coronary artery calcification progression in asymptomatic individuals with initial score of zero.
Koulaouzidis G, Charisopoulou D, Maffrett S, Tighe M, Jenkins PJ, McArthur T.
Angiology. 2013 Oct;64(7):494-7 2012 Sep 11.

81.

Prevalence and distribution of coronary artery calcification in asymptomatic British population.
Koulaouzidis G, Jenkins PJ, McArthur T.
Can J Cardiol. 2013 Jan;29(1):131. 2012 Nov 10..

82.

Differences in clinical profile of individuals with severe and markedly elevated coronary artery calcification detected by electron beam computed tomography.
Koulaouzidis G, Charisopoulou D, Maffrett S, Tighe M, Jenkins PJ, McArthur T.
Angiology. 2013 Aug;64(6):435-9. 2012 Jul 26.

83.

Aggressive and diffuse coronary calcification in South Asian angina patients compared to Caucasians with similar risk factors.
Koulaouzidis G, Nicoll R, Charisopoulou D, McArthur T, Jenkins PJ, Henein MY.
Int J Cardiol. 2013 Sep 10;167(6):2472-6 Epub 2012 Jun 16.

84.

Prevalence of noncalcified coronary plaque in patients with calcium score of 0: the silent enemy.
Koulaouzidis G, Charisopoulou D, Jenkins PJ, Koulaouzidis A, McArthur T.
Angiology. 2013 Apr;64(3):205-10. 2012 Apr 9.